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Abstract
Background: RhoA and RhoC are deregulated by over expression in many human tumors,
including colorectal cancer. Some reports show that they play a pivotal role in the carcinogenesis,
tumor development and infiltration metastasis. In this study, for the first time we constructed
recombinant adenovirus to investigate the inhibitory effects of RhoA and RhoC shRNAs in tandem
expression on the cell proliferation and invasion of colorectal cancer HCT116 cells.
Methods: The recombinant adenovirus carrying RhoA and RhoC shRNAs in tandem expression
was transfected into HCT116. The mRNA transcription and protein expressions of RhoA and
RhoC were examined by RT-FQPCR and Western blot respectively. Cellular proliferation
inhibitory activity was determined by methyl thiazolyl tetrazolium (MTT) assay and invasive and
migrating potential was detected through in vitro Matrigel coated invasion and migration assay.
Results:  Both mRNA and proteins Levels of RhoA and RhoC were significantly reduced in
HCT116 cells transfected with Ad-A1+A2+C1+C2 than those in Ad-HK group and control one.
The relative RhoA and RhoC mRNA transcriptions were decreased to 40% and 36% (P < 0.05),
while proteins expression reducing 42% and 35%, respectively (P < 0.05). Growth curves analysis
showed that alive cell number in the Ad-A1+A2+C1+C2 group was lower than others in the third
to sixth day and transwell chamber analysis showed that migration/invasion activity was significantly
suppressed in Ad-A1+A2+C1+C2 group.
Conclusion: Our results indicate recombinant adenovirus carrying RhoA and RhoC shRNAs in
tandem expression may inhibit the growth and invasion of HCT116 cells. Application of such vector
to inhibit one or more genes may be a new method to cancer therapy.
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Background
The Rho family, a member of the Ras superfamily of low-
molecular-weight GTP-binding proteins, contains Rho
(e.g., RhoA, B, C), Rac and Cdc42 proteins [1,2] Previous
studies have shown that Rho proteins become deregulated
by over expression in tumours. In some cases, this dereg-
ulation correlates with disease progression [3]. Despite
the high homology of different Rho isoforms (RhoA,
RhoB and RhoC), their physiological roles are distinct [4].
The role of RhoB in these processes appears to be more
divergent, whereas RhoA and RhoC proteins have been
shown to have a positive role in proliferation and malig-
nant transformation [5,6]. Moreover, elevated RhoC
expression has been found to correlate with poor outcome
in whites with colorectal carcinoma and may be used as a
prognostic marker of colorectal carcinoma. Increased lev-
els of RhoA expression was observed in Asian patients
with colorectal carcinoma. Therefore, specific inhibiting
the functions of RhoA and RhoC are predicted to be of
great therapeutic benefits. Recently, it has been demon-
strated that interfering the expression of RhoA and RhoC
using small interfering RNA (siRNA) approaches inhib-
ited the proliferation and invasion of gastric cancer cells
[7].
In this study, for the first time we constructed adenovirus
vector carrying RhoA and RhoC shRNAs in tandem
expression and investigated the inhibitory effects of
recombinant adenovirus on the cell proliferation and
invasion of colorectal cancer HCT116 cells. We showed
that a significant reduction in RhoA and RhoC expression
could markedly inhibit the invasion and migration poten-
tials of colorectal cancer cells. Thus, our results provide
new evidence of the potential use of one more gene-tar-
geted RNAi as a novel way to reduce tumor progression of
colorectal cancer.
Methods
Cell culture
The human colon cancer cell line HCT116 was purchased
from China Centre for Type Culture Collection, Chinese
Academy of Sciences. The cells were grown in McCoy's 5A
medium, Modified (Sigma), supplemented with 10% of
fetal bovine serum (Hyclone, USA) at 37°C in a humidi-
fied atmosphere of 5% CO2. Cells were always detached
using Trypsin-EDTA and subcultured at 1.5 × 105 cells per
well into six-well tissue culture plates for transfection.
Cell transfection with adenovirus vectors
Four kinds of oligonucleotide sequences that specifically
knock out human RhoA (NM_001664) and RhoC
(NM_175744) were selected [8]. The oligonucleotide
sequence was as follows: A1: GAAGGCAGAGATAT-
GGCAA, A2: GAAGGATCTTCGGAATGAT, C1: CTATATT-
GCGGACATTGAG, C2: AACATTCCTGAGAAGTGGA.
Scrambled control: GACTTCATAAGGCGCATGC. 4 pairs
shRNA (A1, A2, C1 and C2) were then cloned into the vec-
tor pGenesil-2 (with hU6, mU6, h7SK and hH1 promot-
ers respectively) by repeated excision and ligation
successively. The recombinant adenovirus was generated
by Jingsai biological CO. LTD, Wuhan, China. The particle
titers of the adenoviral stocks were 1 × 109 plaque-forming
units per milliliter (pfu/mL). Adenovirus vectors express-
ing RhoA and RhoC (Ad-A1+A2+C1+C2, A1+A2+C1+C2
in tandem), green fluorescent protein (Ad-GFP) or nega-
tive control (Ad-HK) were used to transfect HCT116 cells.
Transfection efficiency was detected directly by testing the
expression ratio of green fluorescent protein. When mul-
tiplicity of infection (MOI) was 10, HCT116 cells were co-
cultured with Ad-A1+A2+C1+C2 or Ad-HK. The cells were
collected after being transfected for 48 h. Untreated cell
was used as control.
Reverse transcription-fluoresencent quantitative 
polymerase chain reaction (FQ-PCR)
Total RNA was extracted from each sample using Trizol
(Invitrogen, Gaithersburg, MD) and reversely transcripted
into cDNA using the PrimeScript RT-PCR kit (TaKaRa Bio
Inc., Shiga, Japan) according to the manufacturer's
instructions. The primers for the human RhoA gene were:
sense 5'-CGGGAGCTAGCCAAGATGAAG-3', antisense 5'-
CCTTGCAGAGCAGCTCTCGTA-3', fluorescent probe 5'-
FAM-AGAGATATGGCAAACAGGATTGGCG-TAMRA-3',
and the amplicon size is 158 base pairs (bps). The primers
for the human RhoC gene were: sense 5'-CCTCATGTGCT-
TCTCCATCGA-3', antisense 5'-CTCGTCTTGCCTCAG-
GTCCTT-3', fluorescent probe 5'-FAM-
TCTGCCCCAACGTGCCCATCAT-TAMRA-3', and the
amplicon size is 136 bps. The GAPDH was used as the
internal control with the specific primers: sense 5'-
CTTAGCACCCCTGGCCAAG-3', antisense 5'-GATGTTCT-
GGAGAGCCCCG-3', fluorescent probe 5'-FAM-CAT-
GCCATCACTGCCACCCAGAAGA-TAMRA-3', and the
amplicon size is 150 bps. Primers and fluorescent probes
were synthesized by Shanghai Sangon Biological Engi-
neering Technology & Services Co., Ltd. (Shanghai,
China). The levels of RhoA, RhoC and control GAPDH
mRNA transcripts were determined by the QRT-PCR in
ABI7500 real time thermal cycler (Applied Biosystems,
Foster City, CA). The PCR reactions in duplicate were sub-
jected to an initial denaturation at 95°C for 10 seconds,
followed by 40 cycles of denaturation at 95°C for 5 sec-
onds, annealing and extension at 60°C for 45 seconds.
The value of threshold cycle (CT) for each reaction was
recorded.
Western blot analysis
Cell samples were lysed in ice-cold lysis buffer (Beyotime,
China) with 1% PMSF (Phenylmethylsulfonyl fluoride)
for half an hour, then centrifuged at 10,000 g for 20 minJournal of Experimental & Clinical Cancer Research 2009, 28:52 http://www.jeccr.com/content/28/1/52
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at 4°C and the protein concentration of the resulting
supernatant was determined by the bicinchoninic acid
(BCA) protein assay kit (Beyotime, China). Proteins (50
μg) were separated by 12% SDS-PAGE electrophoresis
and subsequently transferred to PVDF membranes. Mem-
branes were blocked with 5% nonfat dry milk in TBS/
Tween 20 (0.05%, v/v) for 2 h at room temperature and
incubated overnight at 4°C with primary antibodies
directing against RhoA (Santa Cruz), RhoC (Santa Cruz)
and GAPDH. The blots were washed and incubated with
the horseradish peroxidase-conjugated secondary anti-
body (DakoCytomation), and developed with a chemilu-
minescent substrate, ECL Plus. An autoradiograph was
obtained, and protein levels were measured using a Fluors
scanner and Quantity One software for analysis (Bio-
Rad). Assays were done in triplicate for each experiment,
and each experiment was repeated three times.
MTT assay
For measurement of cell proliferation rate, the collected
cells, which were transfected with Ad-A1+A2+C1+C2 or
Ad-HK for 48 h, were plated into 96-well plates in 1 × 103
cells/100  μl medium/well. 10 μl of MTT solution
(Amresco) was added into each well daily from the 2nd to
7th day, and plates were incubated for 4 h at 37°C. Then
150 μl DMSO was added to dissolve formazan. Absorb-
ance values (A) were measured at a wavelength of 490 nm
with a microplate reader. Results were expressed as mean
value ± SEM and surviving rate was calculated as the fol-
lows: Surviving rate = A490 of experiment/A490 of control ×
l00%. Assay was done in six wells, and each experiment
was repeated three times.
In vitro matrigel invasion assay
In vitro Matrigel invasion assay was performed by using a
24-well millicell inserts (BD Biosciences) with polycar-
bonate filters (pore size, 8 μm). The upper side of polycar-
bonate filter was coated with matrigel (50 μg/ml, BD
Biosciences). The chambers were incubated at 37°C with
5% CO2 for 2 h to allow the matrix to form a continuous
thin layer. Then the cells transfected with Ad-
A1+A2+C1+C2 or Ad-HK and control ones were harvested
and 4 × 105 cells in 200 μl of 0.1% bovine serum albumin
were placed in the upper chamber. The lower chamber
was filled with 10% serum-medium (700 μl). Cells were
cultured for 22 h at 37°C in 5% CO2. Cells on the upper
surface of the filter were removed using a cotton swab.
Cells invading through the Matrigel and filter to the lower
surface were fixed with 4% neutral-buffered formalin and
stained in 0.01% crystal violet solution. The cell numbers
in five fields (up, down, median, left, right. ×200) were
counted for each chamber, and the average value was cal-
culated. Assays were done in triplicate for each experi-
ment, and each experiment was repeated three times.
In vitro cell migration assay
This migration assay was to measure cell migration
through an 8.0-μm pored membrane in a 24-well millicell
inserts (BD Biosciences). The lower chamber was filled
with 10% serum-medium (700 μl). 4 × 105 cells in 200 μl
medium supplemented with 10% FBS were placed in the
upper chamber. After 16h-incubation, the number of
migrated cells (lower side of the membrane) was counted
as described above.
Statistical analysis
Statistical analyses were performed using SPSS statistical
software (SPSS Inc., Chicago, Illinois). Data were shown
by mean value ± SEM. Differences between two groups
were assessed using a t test. A P value less than 0.05 was
considered statistically significant.
Results
Transfection of HCT116 with adenovirus
Through sequence analysis, the Ad-A1+A2+C1+C2 vector
was identified to be constructed successfully (Fig. 1). To
assess the efficiency of adenoviral transduction, human
HCT116 cells were plated at a density of 1.5 × 105 cells/
well into 24-well plates and infected with Ad-GFP at vari-
ous multiplicities of infection (MOIs) 24 h after seeding.
After 48 h, GFP-expressing cells were detected by fluores-
cence microscopy (Olympus, Japan). We found that
HCT116 cells exhibited high adenoviral transduction effi-
ciency, because more than 95% cells were infected with
Ad-GFP at a dose of MOI 10. We also found that the
number of GFP-expressing cells increased in a MOI-
dependent manner (Fig. 2), but cytotoxicity was gradually
achieved at higher dose of virus (MOI > 20).
Silencing of specific genes and proteins in HCT116
48 hours after transfection of Ad-A1+A2+C1+C2 or Ad-
HK to HCT116, we analyzed the expression of RhoA and
RhoC in mRNA and protein level in HCT116 cells using
real-time FQ-PCR [9] and Western blot assay respectively.
The ΔCT (CTTarget - CTGAPDH) values for RhoA and RhoC
mRNA for cells infected with Ad-A1+A2+C1+C2 were sig-
nificantly higher than those for cells that were infected
with Ad-HK or for the control cells (Fig. 3, Table 1). The
relative RhoA and RhoC mRNA expression to the control
cells were only about 40% and 36%, respectively, which
demonstrated a significantly reduced expression of RhoA
and RhoC mRNA (P < 0.05). However, there was no sig-
nificant difference between the cells treated with Ad-HK
and the control ones (P > 0.05). As shown in Fig. 4, RhoA
and RhoC protein expression was similar to the results of
FQ-PCR. The scanning signal intensity of RhoA and RhoC
proteins for cells infected with Ad-A1+A2+C1+C2 were
significantly weaker than those of control cells or cells
infected with Ad-HK (P < 0.05). The relative RhoA and
RhoC protein expression of cells infected with Ad-Journal of Experimental & Clinical Cancer Research 2009, 28:52 http://www.jeccr.com/content/28/1/52
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shows the sequencing histograms of A1, A2, C1 and C2 of Ad-A1+A2+C1+C2 Figure 1
shows the sequencing histograms of A1, A2, C1 and C2 of Ad-A1+A2+C1+C2. They all contain the sense +loop 
(TTCAAGACG)+antisense.
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displays the expression of GFP in HCT116 cells 48 h after transfected by Ad-GFP with different MOIs under fluorescent micro- scope at 200× magnification Figure 2
displays the expression of GFP in HCT116 cells 48 h after transfected by Ad-GFP with different MOIs under 
fluorescent microscope at 200× magnification. The number of GFP-expressing cells increases in a MOI-dependent man-
ner. When the MOI is more than 20, the infected cells still display bright green fluorescence, but their morphologies changes 
dramatically with less vigorously growing.
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A1+A2+C1+C2 to the control cells were only about 42%
and 35%, respectively (P < 0.05).
Effects of RhoA and RhoC specific shRNA on cell 
proliferation activity
To assess the proliferation activity of tumor cell is impor-
tant in its invasion and metastasis. Collected cells were
seeded onto 96-well microplates and cellular growths
were determined by a continuous 6-day MTT assay.
Growth curve was plotted according to these OD value
alterations of MTT assay. The difference in cell growth
inhibition rate between the HCT116 cells infected with
Ad-A1+A2+C1+C2 and the other two groups was not sta-
tistically significant in the first 2 days. However, in the
third to sixth day, significant differences were found (Fig.
5), but no significant difference between the control cells
and the cells infected with Ad-HK. The results showed that
knockdown of RhoA and RhoC in the HCT116 cells by
shRNA could change the cell proliferation activity in vitro.
Invasion and migration power assay in vitro
After 22 h incubation, the control HCT116 cells showed
stronger invasion activities compared with the ones
infected with Ad-A1+A2+C1+C2 group (88 versus 38)
(Fig. 6). The differences between the control and Ad-HK
group had no statistical significance. Moreover, the
HCT116 cells in Ad-A1+A2+C1+C2 group displayed a sig-
nificantly lower transmembrane migration activity as
compared to those in Ad-HK group and in control
HCT116 cells. These findings suggest that RhoA and RhoC
expression level seems to be closely associated with the
enhanced invasion and migration in HCT116 cell lines.
Discussion
Rho GTPases act as molecular switches to control signal
transduction pathways by cycling between a GDP-bound,
inactive form and a GTP-bound, active form. Their best-
characterized function is in the regulation of actin dynam-
ics. They not only regulate the organization of actin fila-
ment system, but also modulate cell motility,
proliferation, apoptosis, cell cycle progression, and inva-
sion and metastasis of malignant tumor cells [10,11]. Cell
migration is an essential process in multicellular organ-
isms but it's a critical step in tumor invasion and metasta-
sis. Understanding of this process may lead to appropriate
therapies for cancer [12,13]. Recent accumulating evi-
dences have shown that RhoA and RhoC are over-
expressed in many kinds of cancers, and they may play
important roles in initiation and progression of cancers
[3,5,14,15].
Despite the high homology of RhoA and RhoC, RhoA has
been shown to regulate the activities of multiple transcrip-
tion factors, most of which are implicated in the cancer
shows the amplification curve of GAPDH, RhoA and RhoC Figure 3
shows the amplification curve of GAPDH, RhoA and RhoC. They all exhibit standard S shape, suggesting a good ampli-
fication efficiency and linear relationship.
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progression [16] by modulating cancer cell adhesion, con-
traction, movement, release of cellular adhesion, degrada-
tion of extra-cellular matrix, and invasion into blood or
lymph vessels [17,18]. RhoC also contributes to tumor
development, especially to invasion and metastasis of
cancer cells [19,20]. Furthermore, Faried A. and colleagues
identified that RhoA promoted tumour growth more than
RhoC, while RhoC induced distant metastasis in compar-
ison to RhoA [21]. These findings are alike to those of
Clark and colleagues, who showed that RhoC had better
motogen than RhoA when expressed in melanoma and
that RhoC over- expression could promote melanoma
cells to exit the blood and colonise lungs [22].
indicates protein levels in HCT116 cells Figure 4
indicates protein levels in HCT116 cells. The RhoA and RhoC proteins from cells infected with Ad-A1+A2+C1+C2 were 
significantly weaker than those from control cells or from cells infected with Ad-HK. GAPDH is used as a loading control (A). 
The graph (B) compares scanning signal intensity of RhoA and RhoC expression by Imagel software. *P > 0.05, no significantly 
difference between the cells treated with Ad-HK and the control cells. **P < 0.05, compared with other groups.
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Colorectal carcinoma is one of the most common malig-
nancies, with an increasing annual incidence [23]. Color-
ectal carcinoma is usually accompanied by local invasion
and distant metastasis, which are the main causative fac-
tors for the cancer-related death [24]. However, the under-
lying molecular and cellular mechanisms are poorly
understood. Our previous clinical study demonstrated
that the levels of RhoA and RhoC mRNA transcripts in
tumor tissues were significantly higher than those in the
corresponding paratumor and normal tissues, and the
expressions of both RhoA and RhoC in cancers with
lymph node or liver metastasis were significantly higher
than those in those without metastasis, indicating these
two genes may contribute to the onset and development
as well as invasion and metastasis of colorectal carcinoma.
Specifically, the levels of RhoC expression were signifi-
cantly correlated with the extents of local intestinal inva-
sion although not with the histopathological degrees of
cancers, strongly supporting its function in tumor inva-
sion and metastasis [9]. Therefore, specific inhibitors of
individual Rho functions are predicted to be of great ther-
apeutic benefits.
RNA interference (RNAi) is an evolutionarily conserved
sequence-specific post-transcriptional gene silencing
mechanism triggered by small double-stranded RNA
(dsRNA) that results either in degradation of homologues
mRNAs or inhibition of mRNA translation [25]. Many
studies have been done in down-regulating the expression
of RhoA and RhoC by RhoA or RhoC-specific siRNAs to
inhibit the proliferation and invasiveness of cancer cells
[7,26,27]. In this study, we constructed an efficient multi-
ple shRNAs expression system based on pSilence plasmid
and our selected efficient two RhoA-targeted short hairpin
RNAs (shRNA) and two RhoC-targeted shRNAs [8]. The
tandem array multiple shRNAs expression vector con-
tained four shRNA expression cassettes targeting two
genes. In HCT116 cells, the multiple shRNAs expression
constructs could efficiently and simultaneously induce
inhibition of RhoA and RhoC genes and markedly inhibit
the invasion and migration potentials of cancer cells. The
inhibitory effects of multiple shRNAs expression vectors
were more effective than single shRNA expression vector
(data not shown). Further research work is being done to
evaluate the inhibition effects of multiple shRNAs expres-
sion vectors on nude mice.
To our knowledge, this is the first study that 4-tandem
shRNA construct targeting RhoA and RhoC genes was
proved to be a successful approach in reducing the malig-
nance of colorectal tumor cells. Recent accumulating evi-
dences have shown that co-expression of multiple shRNAs
can simultaneously inhibit multiple genes or target multi-
ple sites on a single gene, which demonstrated that multi-
ple shRNAs expression system could inhibit all six genes
and was much more efficient in inducing apoptosis in
PC3 cells [28]. Moreover, a tandem Ku-shRNA-encoding
plasmid expression system can knock-down Ku70 and
Table 1: Expression of RhoA and RhoC mRNA in human HCT116 cells (mean ± SEM)
RhoA RhoC
Groups ΔΔCT Rel. to controla ΔΔCT Rel. to controla
Control 0 ± 0.17 1 (0.88–1.13) 0 ± 0.11 1 (0.93–1.08)
Ad-HK 0.11 ± 0.09 0.93 (0.87–0.99) 0.13 ± 0.10 0.91 (0.85–0.98)
Ad-A1+A2+C1+C2 1.32 ± 0.22 0.40 (0.34–0.47) 1.48 ± 0.16 0.36 (0.32–0.40)
a. Data are expressed as the mean 2-ΔΔCT (range).
displays the growth curve according to the values of 490 nm  wavelength light absorption in the three groups Figure 5
displays the growth curve according to the values of 
490 nm wavelength light absorption in the three 
groups. In the third to sixth day, significant difference as 
exhibited in cell growth inhibition in Ad-A1+A2+C1+C2 
group. But there is a slight difference between the control 
cell and the cells infected with Ad-HK.
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Ku80 at the same time [29]. Furthermore, the vector that
expresses five shRNAs targeting on rat ventricular myocyte
Kir2.1 gene in tandem is able to suppress the expression
of Kir2.1 in rat ventricular myocytes [30]. All these results
including ours implicate that such shRNA-induced in tan-
dem RNA interference may be used for dissecting complex
signaling pathways and even be applied to targeting mul-
tiple genes in cancer therapy.
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indicates that silencing of RhoA and RhoC may inhibit the invasion and migration of HCT116 cells Figure 6
indicates that silencing of RhoA and RhoC may inhibit the invasion and migration of HCT116 cells. The number 
of invading cells was determined by counting the cells stained with 0.01% crystal violet solution in the lower side of the mem-
brane (A). The graphs (B, C) compare the numbers of transmembrane cells in invasion and migration experiments. Data repre-
sent the mean value ± SEM of three independent experiments. *P > 0.05, no significantly difference between the cells treated 
with Ad-HK and the control cells. **P < 0.05, compared with other groups.
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